Fibricor Dosage
Generic name: fenofibric acid
Dosage form: tablet
This dosage information does not include all the information needed to use Fibricor safely and effectively. See full prescribing information for Fibricor.
The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
Dosing Information
FIBRICOR can be given without regard to meals.
Patients should be placed on an appropriate lipid-lowering diet before receiving FIBRICOR and should continue this diet during treatment with fenofibric acid.
Laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting FIBRICOR therapy. Every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. Medications known to exacerbate hypertriglyceridemia (beta blockers, thiazides, estrogens) should be discontinued or changed if possible prior to consideration of triglyceride-lowering drug therapy.
Periodic determination of serum lipids should be obtained during initial therapy in order to establish the lowest effective dose of FIBRICOR. Therapy should be withdrawn in patients who do not have an adequate response after two months of treatment with the maximum recommended dose of 105 mg per day.
Consideration should be given to reducing the dosage of FIBRICOR if lipid levels fall significantly below the targeted range.
Severe Hypertriglyceridemia
The initial dose is 35 to 105 mg per day. Dosage should be individualized according to patient response, and should be adjusted if necessary following repeat lipid determinations at 4 to 8 week intervals. The maximum dose is 105 mg once daily.
Renal Impairment
In patients with mild-to-moderate renal impairment, treatment with FIBRICOR should be initiated at a dose of 35 mg once daily, and increased only after evaluation of the effects on renal function and lipid levels at this dose. The use of FIBRICOR should be avoided in patients with severe renal impairment [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)].
Geriatric Patients
Dose selection for the elderly should be made on the basis of renal function [see Use in Specific Populations (8.5)].
